A case of breast management for a treated case of breast cancer diagnosed as HBOC

Abstract

　In April 2020, BRCA1/2 genetic testing in the diagnosis of hereditary breast and ovarian cancer (HBOC) was approved for funding by social insurance and is now utilized in treatment decisions such as determining surgical approaches for breast cancer patients. However, some breast cancer patients with suspected HBOC were diagnosed before April 2020. The present case was diagnosed with HBOC following the approval of BRCA1/2 genetic testing. She had completed breast-conserving surgery, postoperative chemotherapy, and radiation therapy before BRCA1/2 genetic testing. Here we report a case that required consideration regarding the management of an unaffected ipsilateral conserved breast and contralateral breast.